These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25602714)

  • 1. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
    Growdon WB; Groeneweg J; Byron V; DiGloria C; Borger DR; Tambouret R; Foster R; Chenna A; Sperinde J; Winslow J; Rueda BR
    Gynecol Oncol; 2015 Apr; 137(1):160-6. PubMed ID: 25602714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions.
    Abada E; Kim S; Jang H; Kheil M; Singh K; Bandyopadhyay S; Ali-Fehmi R; Quddus MR
    Gynecol Oncol; 2024 Jun; 185():25-32. PubMed ID: 38364692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
    Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
    Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
    Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
    Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
    Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
    Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
    Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
    Fleming GF; Sill MW; Darcy KM; McMeekin DS; Thigpen JT; Adler LM; Berek JS; Chapman JA; DiSilvestro PA; Horowitz IR; Fiorica JV
    Gynecol Oncol; 2010 Jan; 116(1):15-20. PubMed ID: 19840887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
    Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
    Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
    Diver EJ; Foster R; Rueda BR; Growdon WB
    Oncologist; 2015 Sep; 20(9):1058-68. PubMed ID: 26099744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
    Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.